CD274 and neoplasm: Although MYSTIC did not meet primary endpoints of OS and PFS improvement in metastatic NSCLC patients with PD-L1 expression on ≥25% of tumor cells treated with durvalumab versus chemotherapy, and durvalumab plus tremelimumab versus chemotherapy, the exploratory analysis in a large dataset showed that high blood TMB (defined as ≥16 Mut/Mb) was associated with better OS for durvalumab with tremelimumab versus chemotherapy with a HR of 0.62 (95% CI: 0.451–0.855) and with a two-year OS of 39% of patients versus 18% [49].